PCV18 COST OF ACHIEVING LDL REDUCTION AMONG PATIENTS TREATED WITH EZETIMIBE CO-ADMINISTRATION COMPARED TO STATIN MONOTHERAPY IN THE UK  by Punekar, YS et al.
A314 Paris Abstracts
(n  39,530), three comparing Simvastatin (n  20,859) and three comparing Atorv-
astatin (n  15,553) versus control were retrieved. No head-to-head comparisons 
between these statins in the pre-deﬁned doses were found. All statins were signiﬁcantly 
superior to control in the evaluated outcomes, and the highest risk reductions observed 
were for non-fatal myocardial infarction (MI): Atorvastatin relative risk (RR)  0.57 
(95% CI: 0.44–0.74, I2  0%), Pravastatin RR  0.79 (95% CI: 0.73–0.86, I2  12%), 
 Simvastatin RR  0.62 (95% CI: 0.54–0.70, I2  0%). Indirect comparisons showed 
no statistically signiﬁcant difference between statins in the prevention of total death, 
CV death and stroke. When compared to Pravastatin, the RR of MI for Simvastatin 
was 0.78 (95% CI: 0.67–0.91) and for Atorvastatin was 0.71 (95% CI: 0.54–0.94); 
the comparison between Atorvastatin versus Simvastatin showed no difference (RR  
0.92, 95% CI: 0.68–1.29). CONCLUSIONS: Our results showed similar efﬁcacy 
among these statins in major events reduction in the doses evaluated. Pravastatin seems 
to be less effective than the others in the prevention of MIs. Considering the similar 
results of these drugs, market price must be used in the selection of the most appropri-
ate therapy.
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OBJECTIVES: This study compared blood pressure (BP) outcomes (changes in BP and 
goal attainment) in adult patients (age 18 years) treated with an ARB or ARB-HCTZ 
ﬁxed dose combination. METHODS: A retrospective study was conducted using the 
GE Centricity EMR database, which contains the ambulatory health records for more 
than 11 million US patients. Patients with a physician order for one of the following 
ARBs or ﬁxed-dose combination (FDC) with HCTZ (candesartan, irbesartan, losar-
tan, olmesartan or valsartan) prior to December 2007 were included in the study. 
Demographics, clinical characteristics (co-morbidities, previous antihypertensive medi-
cations) and BP readings at baseline and throughout the 13-month follow-up period 
were recorded. The mean change in systolic and diastolic BPs and percent patients 
attaining BP goal (two consecutive BP readings 140/90 or 130/80 in patients with 
diabetes or renal disease) were recorded. RESULTS: A total of 81,706 patients (60.5% 
female, mean age 61.6 years) receiving an ARB or ARB-HCTZ FDC were identiﬁed. 
Patients with prior antihypertensive medication usage [57,501 (70.4%)] had higher 
baseline BP readings [mean SBP (SD): 147.4 (29.35) vs. 138.7 (18.93) mmHg; mean 
DBP (SD): 84.2 (17.93) vs. 80.8 (12.35)] and also experienced greater reductions in 
BP [mean SBP change (SD): 21.1 (29.61) vs. 13.2 (17.31) mmHg]. At baseline, a 
greater proportion of patients with prior antihypertensive medication usage (57.8% 
vs. 49.5) were not at BP goal. BP goal attainment was similar between the two groups 
(60.6% vs. 62.6%, prior vs. absence, respectively). Mean time to goal (82.8 days vs. 
78.5 days, prior vs. absence, respectively) was also similar between the two groups. 
CONCLUSIONS: Most patients initiating ARB /ARB-HCTZ therapy have utilized 
other antihypertensive medications in the 13 months prior to starting ARBs. Prior 
antihypertensive medication users experienced greater reductions in BP. BP goal 
 attainment was similar between patients with and without prior antihypertensive 
medications.
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OBJECTIVES: Compare combined optimal lipid value (OLV) goal attainment [low-
density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-
C), and triglycerides (TG)] between patients initiating niacin extended-release [NER] 
 simvastatin (NER/S) and ezetimibe  simvastatin (E/S) combination therapies among 
patients in a managed care setting. METHODS: An observational cohort study of 
patients aged  18 initiating NER/S (addition of NER to existing simvastatin therapy) 
or E/S therapy between January 1, 2001 and June 30, 2006 (index date) was performed 
using the HealthCore Integrated Research Database. Patients with a minimum 24 
months of follow-up and diagnosis of cardiovascular disease during the 12 months 
prior to index date were included. A propensity score regression model for treatment 
selection was created after adjusting for age, gender, baseline LDL-C, HDL-C, and 
TG, and Deyo-Charlson comorbidity index (DCI) score. The propensity score was 
included in a multivariate logistic regression model to estimate combined OLV goal 
attainment (per treatment guidelines) between the groups. RESULTS: A total of 883 
patients were identiﬁed initiating NER/S (n  445) or E/S (n  438). E/S patients were 
younger (51.4 o 8.4 years vs. 54.0 o 8.5 years; p  0.001) and less likely to be male 
(55.3% vs. 81.1%; p  0.001). Fewer E/S patients were likely to have prior hyperten-
sion (67.1% vs. 80.2%; p  0.001) and congestive heart disease (17.1% vs. 45.6%; 
p  0.001) versus NER/S patients, though the pre-index DCI score was statistically 
non-signiﬁcant between the groups (0.7 o 1.1: E/S vs. 0.8 o 1.1: NER/S; p  0.097). 
Logistic regression showed that NER/S patients were 64% more likely to achieve 
combined OLV goal attainment as compared to E/S treated patients [Odds Ratio: 1.64 
(95% CI: 1.02—2.62); p  0.04]. CONCLUSIONS: NER/S treatment was associated 
with a likelihood of combined OLV goal attainment versus E/S patients. Further 
research on impact of early initiation of NER/S therapy emphasizing multiple lipid 
parameter management versus LDL-C-only focused treatment strategies comes is 
warranted.
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OBJECTIVES: 1) To compare antihypertensive efﬁcacy of Losartan and Irbesartan 
controlling for baseline Seated Diastolic and Systolic Blood Pressure (SeDBP&SeSBP) 
before treatments, and 2) to compare antihypertensive efﬁcacy of Losartan and 
 Irbesartan between gender controlling for 1) baseline SeDBP&SeSBP, and 2) age. 
METHODS: An experimental design was performed. All hypertensive patients who 
were prescribed 50 mg. Losartan once a day or 150 mg. Irbesartan once a day for 
hypertension during January 1-June 30, 2008 were the population framework. Exclu-
sion criteria included concomitant diseases that would present safety hazards and 
concomitant medications that might interfere with the assessment of efﬁcacy or safety 
e.g., drugs known to affect BP. Simple random technique was employed. The A 0.05, 
power 0.90 and effect size 0.07 were set to generate 200 samples in each group (total 
400). The average baseline SeDBP&SeSBP of Losartan group and Irbesartan group 
were 91.86 o 13.73, 150.76 o 19.14 and 89.56 o 10.69, 148.42 o 15.45 respectively. 
Baseline SeDBP&SeSBP were used as covariates. After medications for eight weeks 
SeDBP&SeSBP were measured and compared. RESULTS: Total 400 (100%) patients, 
mostly 267 (66.80%) were female, 133 (33.33%) were male with average age 63.31 
o 12.52 years. After treatment the average SeDBP of Losartan or Irbesartan groups 
were 77.26 o 9.76 and 74.43 o 9.84 mm. Hg respectively (p  .000, ANCOVA). After 
treatment the average SeSBP of Losartan or Irbesartan groups were 131.72 o 15.17 
and 127.50 o 12.22 mm. Hg respectively (p  .010, ANCOVA). When controlled age 
(covariate) and added gender (ﬁxed factor) to the model, the means of SeDBP&SeSBP 
of Losartan group and Irbesartan group were 77.26 o 9.76, 128.81 o 12.89 and 72.43 
o 9.84, 127.50 o 12.22 mm. Hg respectively (p  0.000 and 0.029, two way ANCOVA 
without gender interaction (p  0.520, 0.101). CONCLUSIONS: Irbesartan 150 mg. 
once a day could signiﬁcantly lower seated systolic and diastolic blood pressure in 
hypertension patients better than Losartan 50 mg. once a day. Gender made no dif-
ferences on efﬁcacy of the two drugs.
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OBJECTIVES: To compare the effectiveness of dual combinations of angiotensin II 
receptor blockers (ARBs) and ACE Inhibitors (ACEIs) with hydrochlorothiazide 
(HCTZ) or Calcium Channel Blockers (CCBs) in reaching target blood pressure (BP) 
in a real-world setting. METHODS: Records from a longitudinal population-based 
database of more than 170,000 patients in over 53 family practice clinics in south-
western Ontario, Canada were analyzed. These records contained chart-abstracted 
information such as visit diagnosis, BP, medications and consultation notes. The 
records from adult non-diabetic patients who were diagnosed with hypertension and 
were initiated on the combination therapy in 2005 and continued on the combination 
for at least 9 months were included. Hypertension was deﬁned as a BP exceeding 
140/90 mmHg, chart entry of a diagnosis of hypertension, or use of anti-hypertensive 
medication. The proportions of patients reaching target BP (BP less than 140/90 mmHg) 
were recorded and the combination of ARBsHCTZ was compared to other combina-
tions. Due to the well known comparable safety proﬁle of the compounds, a safety 
analysis was not performed. RESULTS: A total of 4,458 patients were treated with 
dual combinations of ARBs and ACEIs with HCTZ or CCBs. The proportions of 
patients reaching target BP were 35% on ARBs  HCTZ compared to 30% on 
ACEIsHCTZ (p  0.006), 32% on ARBsCCBs (p  0.03), and 28% on ACEIsCCBs 
(p  0.001). CONCLUSIONS: In the real-world setting, a greater proportion of 
hypertensive patients treated with the dual combination ARBHCTZ reached target 
BP than the dual combinations of ARBCCB, ACEIHCTZ, or ACECCB. Patients 
treated with the combination of an ARB with HCTZ or CCB achieved target BP in a 
greater proportion than patients treated with ACEI-based counterparts.
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BACKGROUND: The randomized double-blind parallel group trial, INPRACTICE, 
demonstrated a signiﬁcant beneﬁt of ezetimibe co-administration with simvastain 
10/40 mg in patients achieving LDL-C targets of 2 mmol/L, compared to atorvastatin 
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40 mg and rosuvastatin 5–10 mg (according to UK label). OBJECTIVES: To estimate 
the cost of treatment for achieving 1 % LDL-C reduction and the cost of getting a 
patient to LDL-C target of 2 mmol/L with ezetimibe co-administered with simvas-
tatin, compared to atorvastatin and rosuvastatin. METHODS: Following a 6-week 
run-in period on 40 mg simvastatin, patients were randomized to receive ezetimibe/
simvastatin 10/40 mg, atorvastatin 40 mg or rosuvastatin 5–10 mg for 6 weeks. The 
total treatment cost for the trial period was estimated. A post-hoc analysis of the trial 
participants was conducted to compare the treatment cost per patient achieving LDL-C 
target of 2 mmol/L between the three comparator treatments. The cost of generic 
simvastatin 40 mg was assumed to be £1.37 for a 28 day treatment (BNF). RESULTS: 
At the end of the 6 week trial period, the treatment cost per 1% reduction in LDL-C 
was estimated to be £1.58 (95% CI: £1.42–£1.79) for ezetimibe co-administered with 
simvastatin. The corresponding treatment costs were £3.33 (£2.64–£4.51) and £9.02 
(£4.59–£450.75) for atorvastatin and rosuvastatin, respectively. Cost per patient 
achieving the LDL-C target of 2 mmol/L was £61.49 (95% CI: £56.66–£67.22) for 
ezetimibe co-administered with simvastatin compared to £101.84 (£87.69–£121.42) 
for atorvastatin and £155.06 (£122.54–£211.12) for rosuvastatin. CONCLUSIONS: 
Co-administration of ezetimibe with simvastatin 40 mg is a cost efﬁcient way of 
reducing LDL-C compared to atorvastatin 40 mg or rosuvastatin 5–10 mg mono-
therapy regimen.
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OBJECTIVES: Antihypertensive therapy is a well-established approach to reducing 
the risk of cardiovascular disease (CVD). The main objective of this meta-analysis was 
to ﬁnd out whether the calcium channel blockers are superior, equal, or inferior to 
other treatments in reducing the frequency of cardiovascular complications. 
METHODS: Studies were identiﬁed through PubMed with a publication date before 
February 24, 2009. We selected studies in hypertension that assessed cardiovascular 
events and included at least 100 patients, who were randomly assigned calcium 
channel blockers or other antihypertensive drugs and who were followed up for at 
least 1 year. The 2 authors independently assessed studies for inclusion and quality. 
We extracted from source documents coronary heart disease, stroke, congestive heart 
failure, cardiovascular disease events, total mortality, cardiovascular disease mortality. 
RESULTS: The 16 eligible studies included 132,078 patients. Calcium channel block-
ers provided more protection against stroke than the conventional therapy consisting 
of diuretics and/or B-blockers (risk ratio 0.86, 95% CI 0.80~0.93) and new antihy-
pertensive drugs, such as angiotensin-converting enzyme inhibitors or angiotensin 
receptor blockers (risk ratio 0.87, 95% CI 0.79~0.96). There were no signiﬁcant dif-
ferences in major cardiovascular events risk, total mortality and cardiovascular disease 
mortality between regimens based on calcium channel blockers and regimens based 
on the conventional therapy (risk ratio 0.98, 95% CI 0.88~1.09; risk ratio 0.98, 95% 
CI 0.90~1.06; risk ratio 0.95, 95% CI 0.83~1.07) or new antihypertensive drugs (risk 
ratio 1.00, 95% CI 0.95~1.05; risk ratio 0.97, 95% CI 0.92~1.02; risk ratio 0.96, 
95% CI 0.89~1.04). CONCLUSIONS: These ﬁndings suggest that calcium channel 
blockers decrease the risk of stroke more effectively than other treatments in patients 
with hypertension. Moreover, when calcium channel blockers were compared with 
new antihypertensive drugs they demonstrated similar reductions in cardiovascular 
morbidity and mortality.
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THE EFFICACY OF CLOPIDOGREL VERSUS THE COMBINATION OF 
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OBJECTIVES: To estimate the relative efﬁcacy of clopidogrel versus low-dose aspirin 
plus extended-release dipyridamole (ASAERDP) in preventing serious vascular events 
among stroke patients. Additionally, to test whether a network meta-analysis (NMA) 
can give reliable estimates of treatments’ relative efﬁcacy in the absence of direct evi-
dence. METHODS: A systematic literature review was conducted in EMBASE and 
MEDLINE to identify randomized controlled trial (RCT) evidence on the endpoint 
“serious vascular events” (including myocardial infarction, stroke and vascular death). 
A NMA with ﬁxed effects was ﬁtted to the data using Winbugs. The NMA was ﬁrst 
run on indirect evidence only (NMA_indirect), and these results were compared with 
results from a NMA including direct and indirect evidence (NMA_all). RESULTS: 
Three RCTs were identiﬁed (ESPS2, ESPRIT, CAPRIE) comparing clopidogrel or 
ASAERDP with aspirin; one RCT (PRoFESS) provided direct evidence, two RCTs 
(CHARISMA and MATCH) provided additional data on clopidogrel through the link 
with aspirinclopidogrel. Furthermore, one meta-analysis (ATC) compared the efﬁ-
cacy of different aspirin dosages; this was added in the network to link the aspirin 
arms which differed in dosage. The odds ratio (OR) of ASAERDP versus clopidogrel 
for NMA_indirect was 1.15 (0.95:1.37); PRoFESS reported 0.99 (0.92:1.07); and 
NMA_all resulted in 1.02 (0.95:1.10). All analyses have OR close to “1” and conﬁ-
dence intervals overlapping “1”. The point estimate of PRoFESS is within the conﬁ-
dence bounds of NMA_indirect, but the OR from these analyses are in opposite 
directions. The conﬁdence interval of NMA_all tightens when adding PRoFESS into 
the network. CONCLUSIONS: The results of the analysis indicate that clopidogrel 
and ASAERDP are of equivalent efﬁcacy in preventing secondary serious vascular 
events. Furthermore, in the absence of direct evidence, statistical techniques such as 
NMA can provide a reasonable estimate of relative efﬁcacy.
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OBJECTIVES: To explore the effectiveness of combination regimens containing 
Angiotensin Receptor Blockers (ARBs) compared to those containing ACE Inhibitors 
(ACEIs) in reaching target blood pressure (BP) in a real-world setting. METHODS: 
Records from a longitudinal population-based database of more than 170,000 patients 
in over 53 family practice clinics in southwestern Ontario, Canada were analyzed. 
These records contained chart-abstracted information such as visit diagnosis, BP, 
medications and consultation notes. The records from adult non-diabetic patients who 
were diagnosed with hypertension and were initiated on combination therapy in 2005 
and continued on the combination for at least 9 months were included. Hypertension 
was deﬁned as a BP exceeding 140/90 mmHg, chart entry of a diagnosis of hyperten-
sion, or use of anti-hypertensive medication. The proportions of patients reaching 
target BP (BP less than 140/90 mmHg) were recorded. Due to the well known com-
parable safety proﬁle of the compounds, a safety analysis was not performed. 
RESULTS: A total of 6160 patients were treated with dual combinations containing 
an ARB or an ACEI. In patients treated with at least one ARB, 39% reached target 
BP compared to 31% of those not treated with an ARB (p  0.004). When comparing 
combinations with HCTZ, 35% and 30% of those on ARB and ACEI, respectively, 
reached target BP (p  0.006). Within the patients treated with an ARB either in dual 
or tri-therapy, 48% of patients irbesartan reached target BP when the ARB was irbe-
sartan compared to 42% for losartan or valsartan (p  0.001 for both), and 41% for 
candesartan (p  0.001). CONCLUSIONS: In a real-world setting, a greater propor-
tion of hypertensive patients treated with a combination containing an ARB reached 
target BP than those treated with a combination not containing an ARB. Within the 
ARB class, a greater proportion of patients treated with a combination containing 
irbesartan reached target BP.
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OBJECTIVES: The objective of this study was to assess diagnostic efﬁcacy and safety 
of implantable loop recorder (ILR) in detection of causes of unexplained or/and recur-
rent syncopes in comparison with conventional diagnostic testing (CDT). METHODS: 
Comparison was based on a systematic review, carried out according to guidelines 
published by Medical Services Advisory Committee (MSAC) and the Agency for 
Health Technology Assessment in Poland. The most important medical databases 
(MEDLINE, EMBASE, CENTRAL) were searched. Two reviewers independently 
selected trials, extracted data and assessed their quality (using QUADAS scale). Quan-
titative analysis was impossible because of heterogeneity between trials with respect 
to baseline characteristic of participants and meaningful differences in duration of 
observation periods between ILR and CDT groups. Assessing speciﬁcity and sensitivity 
of ILR was not possible due to lack of reference tests in included studies. Therefore 
only qualitative analysis was performed. RESULTS: The results of 4 randomized 
control trial (RCTs) and 32 case series (CSs) were included in the analysis. In 3 RCTs 
syndromes (syncope and palpitations) were observed in 42–77% of patients in ILR 
group and 33–73% in CDT group. Determining diagnosis of syncope was successful 
in 33–73% patients with ILR and in 4–21% patients diagnosed by CDT. The results 
from 1 RCT indicate that ILR can prevent implantation of pacemaker in 88% patients 
with unexplained syncope. In CSs syncope and presyncope were reported in 12%-
100% patients and ILR enable to obtain diagnosis in 62,5–100% patients. Medical 
incidents occurred in 2% of patients in CSs. Infections in the insertion site and injuries 
caused by syncope were most commonly reported. Malfunction of the device occurred 
in 51 patients in CSs and 1 patient in RCT. CONCLUSIONS: ILR implantation is 
efﬁcient and safe diagnostic strategy for determine the cause of unexplained or/and 
recurrent syncope.
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OBJECTIVES: This retrospective analysis of a primary care database compares the 
effectiveness of Angiotensin Receptor Blockers (ARBs) used in monotherapy to ACE 
Inhibitors (ACEIs), Calcium Channel Blockers (CCBs), Beta-Blockers (BBs) and diuret-
ics in reaching target blood pressure (BP). METHODS: Records from a longitudinal 
